How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
The Future of Metabolic Health: Beyond GLP-1, Towards Comprehensive Solutions A landmark review published in The Lancet confirms what many clinicians are witnessing: modern incretin-based drugs are fundamentally changing how we approach obesity, type 2 diabetes (T2D), and related health issues. But the story doesn’t end with semaglutide and tirzepatide. The research points towards a … Read more